Since the majority of patients with classical cardiovascular risk factors (e.g. diabetes, dyslipidemia, hypertension etc.)were already treated, we cannot rule out the plausible effects of pharmaceutical agents (e.g. statins) on RBP4, leading to underestimation of its predictive power. The gene discussed is RBP4; the disease is metabolic syndrome.